Explaining Why Increases in Generic Use Outpace Decreases in Brand Name Medicine Use in Multisource Markets and the Role of Regulation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 May 2

PMID 38696520

Authors

Katharina E Blankart

Sotiris Vandoros

Affiliations

Soon will be listed here.

Abstract

Background: Healthcare systems worldwide face escalating pharmaceutical expenditures despite interventions targeting pricing and generic substitution. Existing studies often overlook unwarranted volume increases in multisource markets due to differential physician perceptions of brand name and generics.

Objective: This study aims to explain the outpacing of generic medicine use over brand name use in multisource markets and assess the regulatory role, specifically examining the impact of reference pricing on volume and intensity increases.

Methods: Analyzing German multisource prescription medicine markets from 2011 to 2014, we evaluate regulatory mechanisms and explore whether brand name and generic medicines constitute separate market segments. Using an Oaxaca-Blinder decomposition approach, we divide the differential in brand name versus generic medicine use rates into market structure and unobserved segment effects.

Results: Generic use rates surpass same-market brand name substitution by 3.87 prescriptions per physician and medicine, on average. Reference pricing mitigated volume increase, treatment intensity and expenditure. Disparities in quantity and expenditure dynamics between brand name and generic segments are partially explained by market structure and segment effects.

Conclusion: Generic medicine use effectively reduces expenditures but contributes to increased net prescription rates. Reference pricing may control medicine use, but divergent physician perceptions of brand name and generics, revealed by identified segment effects, call for nuanced policy interventions.

Citing Articles

The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis.

Schroder L, Seifert R Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39570381 DOI: 10.1007/s00210-024-03615-5.

References

Vandoros S . Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors. Health Econ. 2013; 23(5):621-30. DOI: 10.1002/hec.2935. View

Dieleman J, Squires E, Bui A, Campbell M, Chapin A, Hamavid H . Factors Associated With Increases in US Health Care Spending, 1996-2013. JAMA. 2017; 318(17):1668-1678. PMC: 5818797. DOI: 10.1001/jama.2017.15927. View

Danzon P, Ketcham J . Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res. 2004; 7:1-54. DOI: 10.2202/1558-9544.1050. View

Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D . The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Appl Health Econ Health Policy. 2015; 13 Suppl 1:S21-33. PMC: 4519629. DOI: 10.1007/s40258-014-0147-0. View

Granlund D . Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?. Soc Sci Med. 2009; 69(11):1643-50. DOI: 10.1016/j.socscimed.2009.09.016. View

Crea G, Galizzi M, Linnosmaa I, Miraldo M . Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data. J Health Econ. 2019; 65:153-169. DOI: 10.1016/j.jhealeco.2019.03.006. View

Fischer K, Stargardt T . The diffusion of generics after patent expiry in Germany. Eur J Health Econ. 2015; 17(8):1027-1040. DOI: 10.1007/s10198-015-0744-3. View

Bundorf M, Royalty A, Baker L . Health care cost growth among the privately insured. Health Aff (Millwood). 2009; 28(5):1294-304. DOI: 10.1377/hlthaff.28.5.1294. View

Zhou Z, Rahme E, Pilote L . Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006; 151(2):273-81. DOI: 10.1016/j.ahj.2005.04.003. View

10.

Cutler D, Skinner J, Stern A, Wennberg D . Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spendingf. Am Econ J Econ Policy. 2020; 11(1):192-221. PMC: 7444804. DOI: 10.1257/pol.20150421. View

11.

Shrank W, Liberman J, Fischer M, Avorn J, Kilabuk E, Chang A . The consequences of requesting "dispense as written". Am J Med. 2011; 124(4):309-17. DOI: 10.1016/j.amjmed.2010.11.020. View

12.

Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kosters J . Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014; (10):CD005979. PMC: 6703418. DOI: 10.1002/14651858.CD005979.pub2. View

13.

Herr A, Suppliet M . Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals. J Health Econ. 2017; 56:19-29. DOI: 10.1016/j.jhealeco.2017.08.008. View

14.

Hellerstein J . The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ. 1999; 29(1):108-36. View

15.

Berndt E . The U.S. pharmaceutical industry: why major growth in times of cost containment?. Health Aff (Millwood). 2001; 20(2):100-14. DOI: 10.1377/hlthaff.20.2.100. View

16.

Birkner B, Blankart K . The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany. Value Health. 2022; 25(9):1528-1538. DOI: 10.1016/j.jval.2022.03.005. View

17.

Kanavos P, Ferrario A, Vandoros S, Anderson G . Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood). 2013; 32(4):753-61. DOI: 10.1377/hlthaff.2012.0920. View

18.

Fischer K, Koch T, Kostev K, Stargardt T . The impact of physician-level drug budgets on prescribing behavior. Eur J Health Econ. 2017; 19(2):213-222. DOI: 10.1007/s10198-017-0875-9. View

19.

Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152-60. DOI: 10.1016/s0002-9149(03)00530-7. View

20.

Jones P, Kafonek S, Laurora I, Hunninghake D . Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81(5):582-7. DOI: 10.1016/s0002-9149(97)00965-x. View